CN109481689A - 一种增强姜黄素水溶性的组合物及其制备方法 - Google Patents
一种增强姜黄素水溶性的组合物及其制备方法 Download PDFInfo
- Publication number
- CN109481689A CN109481689A CN201811588310.4A CN201811588310A CN109481689A CN 109481689 A CN109481689 A CN 109481689A CN 201811588310 A CN201811588310 A CN 201811588310A CN 109481689 A CN109481689 A CN 109481689A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- water
- phosphatide
- composition
- enhancing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 258
- 239000004148 curcumin Substances 0.000 title claims abstract description 129
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 129
- 229940109262 curcumin Drugs 0.000 title claims abstract description 129
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229920001353 Dextrin Polymers 0.000 claims abstract description 33
- 239000004375 Dextrin Substances 0.000 claims abstract description 33
- 235000019425 dextrin Nutrition 0.000 claims abstract description 33
- 150000002327 glycerophospholipids Chemical class 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 235000019441 ethanol Nutrition 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- 229940083466 soybean lecithin Drugs 0.000 claims description 14
- 239000000469 ethanolic extract Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims description 5
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims description 5
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 235000013325 dietary fiber Nutrition 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- MUYJSOCNDLUHPJ-UHFFFAOYSA-N bishydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-UHFFFAOYSA-N 0.000 claims description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims description 2
- MUYJSOCNDLUHPJ-XVNBXDOJSA-N dihydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-XVNBXDOJSA-N 0.000 claims description 2
- BWHPKBOLJFNCPW-UHFFFAOYSA-N dihydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)C=C(O)C=CC=2C=C(OC)C(O)=CC=2)=C1 BWHPKBOLJFNCPW-UHFFFAOYSA-N 0.000 claims description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001095 phosphatidyl group Chemical group 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- VAIMBRBKSOAYTD-UHFFFAOYSA-N phosphorous acid;propane-1,2,3-triol Chemical compound OP(O)O.OCC(O)CO VAIMBRBKSOAYTD-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 30
- 229960004756 ethanol Drugs 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000010010 raising Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OMEBXAYMRCYOTB-UHFFFAOYSA-N [P].OCC(O)CO Chemical compound [P].OCC(O)CO OMEBXAYMRCYOTB-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- -1 polyphenol compound Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种增强姜黄素水溶性的组合物及其制备方法,属于食品及保健品技术领域。本发明所述的组合物包含如下重量份的组分:姜黄素或其衍生物0.1~35.0份、含磷酸甘油酯的磷脂或磷酸甘油酯0.03~560.0份、抗性糊精0.2~70.0份。本发明组合物中,磷酸甘油酯和抗性糊精协同增强了本发明组合物的溶出度、释放度、姜黄素的体内转运效率、生物利用度,改善了脂溶性姜黄素在肠段吸收状况,在不影响姜黄素原有特性及抗氧化性情况下,扩宽了姜黄素固体制剂的种类形式及其功能应用范围。
Description
技术领域
本发明涉及一种增强姜黄素水溶性的组合物及其制备方法,属于食品及保健品技术领域。
背景技术
姜黄素是一种多酚类化合物,着色能力强,是世界上销量最大的七大天然食用色素之一,是被世界卫生组织和美国食品药品监督管理局公认的天然食品添加剂。姜黄素分子中含有多个双键,同时还有酚羟基和羰基等活性基团,在抗肿瘤,抗氧化、清除自由基,抗微生物以及对心血管系统,消化系统,炎症引起的骨关节炎、癌症,类风湿性关节炎,溃疡性肠炎,心血管疾病等方面均有疗效。但其生物利用度低限制了它在保健、医药方面的应用。国内外研究姜黄素在药物中的应用时,发现姜黄素与磷脂、胡椒碱、表面活性剂等物质复合,能改善姜黄素的吸收利用度,成为其它脂溶性药物增溶的载体。
抗性糊精是低分子水溶性膳食纤维,具有易溶解性、低粘度、酸稳定性、压热稳定性、冷冻解冻稳定性、低褐变性、储存稳定性、包裹物质等特性。本发明发现,乳化剂甘油磷酸酯能使姜黄素在水中呈稳定的溶胀状态,加入水溶性抗性糊精为缔合的姜黄素赋型,可以协同增加缔合的姜黄素的水溶性,并提高缔合的姜黄素的生物利用度,改善了脂溶性姜黄素在肠段吸收状况,不影响姜黄素原有特性及抗氧化性,并易于后续制备固体制剂。
姜黄素、甘油磷酸酯、抗性糊精是普通可食用物质,长期服用安全性高,适合制备功能性的特殊食品。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种增强姜黄素水溶性的组合物及其制备方法,本发明的组合物能增加姜黄素的水溶性,提高姜黄素的生物利用度,改善姜黄素在肠段吸收状况,扩宽姜黄素固体制剂的种类形式及其功能应用范围。
为实现上述目的,本发明采取的技术方案为:一种增强姜黄素水溶性的组合物,所述组合物包含如下重量份的组分:姜黄素或其衍生物0.1~35.0份、含磷酸甘油酯的磷脂或磷酸甘油酯0.03~560.0份、抗性糊精0.2~70.0份。
作为本发明所述增强姜黄素水溶性的组合物的优选实施方式,所述组合物包含如下重量份的组分:姜黄素或其衍生物0.24~0.32份、含磷酸甘油酯的磷脂或磷酸甘油酯0.73~1.56份、抗性糊精0.48~0.64份。
作为本发明所述增强姜黄素水溶性的组合物的优选实施方式,所述姜黄素或其衍生物为姜黄素、脱甲氧基姜黄素、双脱甲氧基姜黄素、二氢姜黄素、四氢姜黄素中的至少一种。
作为本发明所述增强姜黄素水溶性的组合物的优选实施方式,所述含磷酸甘油酯的磷脂为大豆磷脂、鸡蛋磷脂中的至少一种,所述磷酸甘油酯为磷脂酰胆碱、磷脂酰丝氨酸、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰甘油、甘油磷脂酸、二磷脂酰甘油中的至少一种。
作为本发明所述增强姜黄素水溶性的组合物的优选实施方式,所述抗性糊精为低分子水溶性膳食纤维,其制备方法为:以食用淀粉为原料,在酸性条件下经糊精化反应制得。
第二方面,本发明提供了上述增强姜黄素水溶性的组合物的制备方法,包括以下步骤:
(1)按配比称取姜黄素或其衍生物、含磷酸甘油酯的磷脂或磷酸甘油酯、抗性糊精;
(2)将含磷酸甘油酯的磷脂或磷酸甘油酯、乙醇,置于常规提取搅拌罐中,提取,过滤,得到磷脂乙醇提取液;
(3)将姜黄素或其衍生物、步骤(2)得到的磷脂乙醇提取液、乙醇,置于常规提取搅拌罐中,缔合,得到姜黄素缔合液;
(4)将步骤(3)得到的姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将步骤(4)得到的姜黄素缔合浓缩液与抗性糊精水溶液混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
本发明制备方法中用到的仪器为常规提取罐、超临界二氧化碳提取机、双效浓缩机、多效浓缩机、膜浓缩机、真空旋转蒸发机、喷雾干燥机、沸腾干燥机、流化床喷雾干燥机、冷冻干燥机、三维混合机、双锥混合机、V型混合机、二维混合机中的至少一种。
作为本发明所述增强姜黄素水溶性的组合物的制备方法的优选实施方式,所述步骤(2)中,乙醇为95%乙醇,含磷酸甘油酯的磷脂或磷酸甘油酯与乙醇的质量体积比为1:(10~20),提取时间为4h。
作为本发明所述增强姜黄素水溶性的组合物的制备方法的优选实施方式,所述步骤(3)中,乙醇为95%乙醇,姜黄素或其衍生物与乙醇的质量体积比为1:(40~200),缔合时间为8h。
第三方面,本发明提供了上述增强姜黄素水溶性的组合物在制备保健品或食品中的用途。
与现有技术相比,本发明的有益效果为:
(1)乳化剂磷酸甘油酯能令姜黄素在水中呈稳定的溶胀状态,不影响姜黄素原有特性,与抗性糊精组合,协同增加本发明组合物的水溶性。与姜黄素相比:①本发明组合物的释放度和油水分配系数均大于1,水溶性提高了约6倍;②在SD大鼠试验中,本发明组合物的血药浓度达峰时间30分钟(与姜黄素一致),峰值时间下峰浓度(Cmax)提高了近10倍,血药浓度-时间曲线面积(AUC0~∞)提高了6.7倍。说明本发明组合物的溶出度、释放度、姜黄素的体内转运效率、生物利用度均得到增强,姜黄素在肠段吸收状况得以改善,易于后续制备固体制剂。
(2)抗性糊精对缔合的姜黄素作用:①不影响缔合的姜黄素的最终品质,改善缔合物的口感;②为缔合的姜黄素赋型,协同增加缔合的姜黄素的水溶性,及提高缔合的姜黄素的生物利用度,有助于后续制备多种固体制剂;③在不添加抗氧化剂情况下,抗性糊精的包裹作用能避免本发明组合物的各种氧化可能性,延长本发明组合物的起效时间。
(3)在本发明的组合物中,姜黄素、磷酸甘油酯、抗性糊精是普通可食用物质,长期服用安全性高,适合制备功能性食品;原料来源广泛,组分搭配简单,固体制剂辅料种类和用量少,功效明确,能组合生产多种剂型产品。
(4)本发明组合物中,磷酸甘油酯和抗性糊精协同增强了本发明组合物的溶出度、释放度、姜黄素的体内转运效率、生物利用度,改善了脂溶性姜黄素在肠段吸收状况,在不影响姜黄素原有特性及抗氧化性情况下,扩宽了姜黄素固体制剂的种类形式及其功能应用范围。
具体实施方式
为更好地说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
实施例1
一种增强姜黄素水溶性的组合物,包含如下质量的组分:姜黄素0.9kg,大豆磷脂14.0kg,抗性糊精1.8kg。
本实施例增强姜黄素水溶性的组合物的制备方法如下:
(1)称取姜黄素0.9kg,大豆磷脂14.0kg,抗性糊精1.8kg,95%乙醇275.0L;
(2)将大豆磷脂14.0kg、95%乙醇140.0L,置于提取搅拌罐中,提取4h,5μm滤器过滤,得到磷脂乙醇提取液;
(3)将姜黄素0.9kg、磷脂乙醇提取液、95%乙醇135.0L,置于提取搅拌罐中,缔合8h,得到姜黄素缔合液;
(4)将姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将姜黄素缔合浓缩液与抗性糊精1.8kg水溶液混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
实施例2
一种增强姜黄素水溶性的组合物,包含如下质量的组分:姜黄素3.5kg,大豆磷脂1.2kg,抗性糊精7.0kg。
本实施例增强姜黄素水溶性的组合物的制备方法如下:
(1)称取姜黄素3.5kg,大豆磷脂1.2kg,抗性糊精7.0kg,95%乙醇718.0L;
(2)将大豆磷脂1.2kg、95%乙醇18.0L,置于提取搅拌罐中,提取4h,5μm滤器过滤,得到磷脂乙醇提取液;
(3)将姜黄素3.5kg、磷脂乙醇提取液、95%乙醇700.0L,置于提取搅拌罐中,缔合8h,得到姜黄素缔合液;
(4)将姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将姜黄素缔合浓缩液与抗性糊精7.0kg水溶液,混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
实施例3
一种增强姜黄素水溶性的组合物,包含如下质量的组分:姜黄素1.0kg,大豆磷脂6.0kg,抗性糊精2.0kg。
本实施例增强姜黄素水溶性的组合物的制备方法如下:
(1)称取姜黄素1.0kg,大豆磷脂6.0kg,抗性糊精2.0kg,95%乙醇160.0L;
(2)将大豆磷脂6.0kg、95%乙醇120.0L,置于提取搅拌罐中,提取4h,5μm滤器过滤,得到磷脂乙醇提取液;
(3)将姜黄素1.0kg、磷脂乙醇提取液、95%乙醇40.0L,置于提取搅拌罐中,缔合8h,得到姜黄素缔合液;
(4)将姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将姜黄素缔合浓缩液与抗性糊精2.0kg水溶液,混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
实施例4
一种增强姜黄素水溶性的组合物,包含如下质量的组分:姜黄素1.4kg,大豆磷脂0.35kg,抗性糊精2.8kg。
本实施例增强姜黄素水溶性的组合物的制备方法如下:
(1)称取姜黄素1.4kg,大豆磷脂0.35kg,95%乙醇115.5L,抗性糊精2.8kg;
(2)将大豆磷脂0.35kg、95%乙醇3.5L,置于提取搅拌罐中,提取4h,5μm滤器过滤,得到磷脂乙醇提取液;
(3)将姜黄素1.4kg、磷脂乙醇提取液、95%乙醇112.0L,置于提取搅拌罐中,缔合8h,得到姜黄素缔合液;
(4)将姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将姜黄素缔合浓缩液与抗性糊精2.8kg水溶液,混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
效果例1本发明实施例1的药动学试验
试验物料:SD大鼠18只,SPF级,雄性,体重200±10g。饲养室温度20~25℃,相对湿度40~60%。饲料由蛋白质、脂肪、碳水化合物组成,饮用水是去离子水。待大鼠适应环境后,禁食12小时,称量体重,测量体长,随机分2组饲养,9只/组。
剂量设计:姜黄素作为对照样品,参考预试验用量,按姜黄素浓度为360mg/kg/d,折算本发明组合物的取样量。
样品组设计:采用姜黄素作为对照样品,给对照组大鼠用;本发明实施例1制备的组合物作为试验样品,给试验组大鼠用。
试验方法:用羧甲基纤维素钠把试验组和对照组样品分别配制成混悬液170mg/mL。待大鼠禁食12小时后,给各大鼠灌胃2ml。给药后各于5分钟、15分钟、30分钟、45分钟、60分钟、90分钟、120分钟、180分钟时取眼眶血,离心,处理血浆作为样品,采用高效液相法进行测定。
统计学处理:采用DAS3.0软件对所得到的药时曲线进行统计分析,记录以下药动学参数数据:血药浓度达峰时间(Tmax),峰值时间下峰浓度(Cmax),时间点下血药浓度-时间曲线面积(AUC0~t),血药浓度-时间曲线面积(AUC0~∞),结果如表1所示。
表1
Tmax(min) | Cmax(mg/mL) | AUC<sub>0~t</sub> | AUC<sub>0~∞</sub> | |
对照组 | 30 | 0.024 | 2.381 | 4.266 |
试验组 | 30 | 0.237 | 20.879 | 28.377 |
由表1可知,对照组和试验组的血药浓度达峰时间均为30分钟。与姜黄素相比,本发明实施例1组合物的Cmax提高了9.9倍(近10倍)、AUC0~∞提高了6.7倍。说明本发明实施例1的组合物在大鼠身上的生物利用度得到了提高。效果例2本发明组合物的水溶性试验
试验物料:姜黄素;实施例1~3的步骤(4)的留样浓缩液,浓缩至没有乙醇,得到姜黄素缔合浓缩物;实施例4的组合物。
样品组设计:姜黄素的无水乙醇溶液,作为外标样品组;姜黄素的水溶液,作为对照品组;实施例1~3的姜黄素缔合浓缩物,对应地作为试验样品组1~3;实施例4的组合物,作为试验样品组4。
试验方法:按预试验结果知,4μg/mL的姜黄素无水乙醇液是全溶状态,在紫外430nm下,吸光度0.609,将此溶液作为外标样品组。
在100mL水中,过量地加入姜黄素;在37℃下振摇24h,过滤取清滤液;取1mL清滤液,用无水乙醇稀释至10mL,在紫外430nm下,测吸光度;将此溶液作为对照品组。
在100mL水中,过量地加入实施例1的姜黄素缔合浓缩物;在37℃下振摇24h,离心取上清液;取1mL上清液,用无水乙醇稀释至10mL;在紫外430nm下,测吸光度;将此溶液作为试验样品组1。按此法,制备试验样品组2和试验样品组3。
在100mL水中,过量地加入实施例4的组合物;在37℃下振摇24h,离心取上清液,取1mL上清液,用无水乙醇稀释至10mL;在紫外430nm下,测吸光度;将此溶液作为试验样品组4。
计算方法:通过外标样品的浓度和吸光度,及对照品、试验样品的吸光度,计算对照品、试验样品的浓度和溶解度。结果如表2所示。
表2
浓度(μg/mL) | 吸光度值 | 溶解度(mg/100mL) | |
外标样品组 | 4 | 0.609 | —— |
对照品组 | 0.572 | 0.087 | 7.14 |
试验样品组1 | 3.417 | 0.520 | 42.71 |
试验样品组2 | 3.561 | 0.542 | 44.51 |
试验样品组3 | 3.528 | 0.537 | 44.13 |
试验样品组4 | 3.542 | 0.548 | 63.15 |
由表2可知,4个试验样品组在水溶液中的溶解度均比对照品组的高6倍以上,表明缔合后姜黄素的水溶性比姜黄素的水溶性明显增强。其中,试验样品组4的溶解度比试验样品组1~3的都提高,表明抗性糊精的加入,能协同增强缔合后的姜黄素的水溶性。
效果例3
本发明组合物中各组分的配比影响组合物的效果,为考察各组分配比对组合物效果的影响,申请人按照本发明的制备方法制备了试验组和对照组组合物,并按照效果例1和效果例2的试验方法,对试验组和对照组组合物进行性能测试。
本效果例中,试验组和对照组的各组分配比如表3所示,试验结果如表3所示。
表3
由表3可知,当各组分配比在本发明范围之内时,本发明的组合物具有较好的生物利用度和水溶性;当姜黄素或其衍生物为0.24~0.32重量份、含磷酸甘油酯的磷脂或磷酸甘油酯为0.73~1.56重量份、抗性糊精为0.48~0.64重量份时,本发明的组合物具有更好的生物利用度和水溶性。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (9)
1.一种增强姜黄素水溶性的组合物,其特征在于,所述组合物包含如下重量份的组分:姜黄素或其衍生物0.1~35.0份、含磷酸甘油酯的磷脂或磷酸甘油酯0.03~560.0份、抗性糊精0.2~70.0份。
2.如权利要求1所述的增强姜黄素水溶性的组合物,其特征在于,所述组合物包含如下重量份的组分:姜黄素或其衍生物0.24~0.32份、含磷酸甘油酯的磷脂或磷酸甘油酯0.73~1.56份、抗性糊精0.48~0.64份。
3.如权利要求1或2所述的增强姜黄素水溶性的组合物,其特征在于,所述姜黄素或其衍生物为姜黄素、脱甲氧基姜黄素、双脱甲氧基姜黄素、二氢姜黄素、四氢姜黄素中的至少一种。
4.如权利要求1或2所述的增强姜黄素水溶性的组合物,其特征在于,所述含磷酸甘油酯的磷脂为大豆磷脂、鸡蛋磷脂中的至少一种,所述磷酸甘油酯为磷脂酰胆碱、磷脂酰丝氨酸、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰甘油、甘油磷脂酸、二磷脂酰甘油中的至少一种。
5.如权利要求1或2所述的增强姜黄素水溶性的组合物,其特征在于,所述抗性糊精为低分子水溶性膳食纤维,其制备方法为:以食用淀粉为原料,在酸性条件下经糊精化反应制得。
6.如权利要求1~5任一项所述的增强姜黄素水溶性的组合物的制备方法,其特征在于,包括以下步骤:
(1)按配比称取姜黄素或其衍生物、含磷酸甘油酯的磷脂或磷酸甘油酯、抗性糊精;
(2)将含磷酸甘油酯的磷脂或磷酸甘油酯、乙醇,置于常规提取搅拌罐中,提取,过滤,得到磷脂乙醇提取液;
(3)将姜黄素或其衍生物、步骤(2)得到的磷脂乙醇提取液、乙醇,置于常规提取搅拌罐中,缔合,得到姜黄素缔合液;
(4)将步骤(3)得到的姜黄素缔合液,置于双效浓缩机中,浓缩,得到姜黄素缔合浓缩液;
(5)将步骤(4)得到的姜黄素缔合浓缩液与抗性糊精水溶液混合均匀,置于喷雾干燥机中,喷雾,得到组合物。
7.如权利要求6所述的增强姜黄素水溶性的组合物的制备方法,其特征在于,所述步骤(2)中,乙醇为95%乙醇,含磷酸甘油酯的磷脂或磷酸甘油酯与乙醇的质量体积比为1:(10~20),提取时间为4h。
8.如权利要求6所述的增强姜黄素水溶性的组合物的制备方法,其特征在于,所述步骤(3)中,乙醇为95%乙醇,姜黄素或其衍生物与乙醇的质量体积比为1:(40~200),缔合时间为8h。
9.如权利要求1~5任一项所述的增强姜黄素水溶性的组合物在制备保健品或食品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811588310.4A CN109481689B (zh) | 2018-12-25 | 2018-12-25 | 一种增强姜黄素水溶性的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811588310.4A CN109481689B (zh) | 2018-12-25 | 2018-12-25 | 一种增强姜黄素水溶性的组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109481689A true CN109481689A (zh) | 2019-03-19 |
CN109481689B CN109481689B (zh) | 2021-12-03 |
Family
ID=65711868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811588310.4A Active CN109481689B (zh) | 2018-12-25 | 2018-12-25 | 一种增强姜黄素水溶性的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109481689B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110214950A (zh) * | 2019-06-04 | 2019-09-10 | 秦皇岛大惠生物技术有限公司 | 姜黄素水分散剂的制备方法 |
CN110772567A (zh) * | 2019-08-21 | 2020-02-11 | 杭州娃哈哈科技有限公司 | 一种蔓越莓微泡腾片及其制备方法 |
CN111543636A (zh) * | 2020-06-03 | 2020-08-18 | 王京杭 | 一种黄酮高纤组合物及其制备方法 |
CN112716896A (zh) * | 2020-09-21 | 2021-04-30 | 完美(中国)有限公司 | 一种姜黄全提物纳米乳固体制剂及其制备方法 |
CN113244254A (zh) * | 2021-03-26 | 2021-08-13 | 浙江工业大学 | 一种增强金黄霉素a水溶性的组合物及其制备与应用 |
CN115813780A (zh) * | 2022-03-30 | 2023-03-21 | 广东格烯生物科技股份有限公司 | 一种含四氢姜黄素的纳米级祛黄组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1657040A (zh) * | 2004-11-22 | 2005-08-24 | 山东大学 | 姜黄素磷脂复合物及其制备方法 |
CN1709228A (zh) * | 2005-06-09 | 2005-12-21 | 中山大学 | 姜黄素固体分散体及其制备方法与应用 |
CN102068419A (zh) * | 2010-12-28 | 2011-05-25 | 神威药业有限公司 | 一种姜黄素组合物 |
US20140010903A1 (en) * | 2012-07-04 | 2014-01-09 | Akay Flavours & Aromatics Pvt Ltd. | Curcuminoid composition with enhanced bioavailability and a process for its preparation |
CN105054076A (zh) * | 2015-08-25 | 2015-11-18 | 广州施健生物科技有限公司 | 一种有助于改善阿尔兹海默症的营养组合物及其应用 |
CN107213467A (zh) * | 2017-05-22 | 2017-09-29 | 江苏大学 | 一种姜黄素磷脂复合物的制备方法 |
-
2018
- 2018-12-25 CN CN201811588310.4A patent/CN109481689B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1657040A (zh) * | 2004-11-22 | 2005-08-24 | 山东大学 | 姜黄素磷脂复合物及其制备方法 |
CN1709228A (zh) * | 2005-06-09 | 2005-12-21 | 中山大学 | 姜黄素固体分散体及其制备方法与应用 |
CN102068419A (zh) * | 2010-12-28 | 2011-05-25 | 神威药业有限公司 | 一种姜黄素组合物 |
US20140010903A1 (en) * | 2012-07-04 | 2014-01-09 | Akay Flavours & Aromatics Pvt Ltd. | Curcuminoid composition with enhanced bioavailability and a process for its preparation |
CN105054076A (zh) * | 2015-08-25 | 2015-11-18 | 广州施健生物科技有限公司 | 一种有助于改善阿尔兹海默症的营养组合物及其应用 |
CN107213467A (zh) * | 2017-05-22 | 2017-09-29 | 江苏大学 | 一种姜黄素磷脂复合物的制备方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110214950A (zh) * | 2019-06-04 | 2019-09-10 | 秦皇岛大惠生物技术有限公司 | 姜黄素水分散剂的制备方法 |
CN110772567A (zh) * | 2019-08-21 | 2020-02-11 | 杭州娃哈哈科技有限公司 | 一种蔓越莓微泡腾片及其制备方法 |
CN110772567B (zh) * | 2019-08-21 | 2021-09-07 | 杭州娃哈哈科技有限公司 | 一种蔓越莓微泡腾片及其制备方法 |
CN111543636A (zh) * | 2020-06-03 | 2020-08-18 | 王京杭 | 一种黄酮高纤组合物及其制备方法 |
CN112716896A (zh) * | 2020-09-21 | 2021-04-30 | 完美(中国)有限公司 | 一种姜黄全提物纳米乳固体制剂及其制备方法 |
CN113244254A (zh) * | 2021-03-26 | 2021-08-13 | 浙江工业大学 | 一种增强金黄霉素a水溶性的组合物及其制备与应用 |
CN113244254B (zh) * | 2021-03-26 | 2023-03-14 | 浙江工业大学 | 一种增强金黄霉素a水溶性的组合物及其制备与应用 |
CN115813780A (zh) * | 2022-03-30 | 2023-03-21 | 广东格烯生物科技股份有限公司 | 一种含四氢姜黄素的纳米级祛黄组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109481689B (zh) | 2021-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109481689A (zh) | 一种增强姜黄素水溶性的组合物及其制备方法 | |
US20160151440A1 (en) | A Novel Composition of Curcumin with Enhanced Bioavailability | |
MX2008012066A (es) | Extractos y metodos que comprenden especies de ganoderma. | |
US11642316B2 (en) | Water-soluble curcumin mixture with high bioavailability and preparation method and application thereof | |
CN100594898C (zh) | 水飞蓟宾的药用组合物及其制备方法 | |
KR20200118456A (ko) | 베르베린을 포함하는 조성물 | |
DE102013011026A1 (de) | Zusammensetzung eines Nahrungsmittelzusatzstoffes | |
JP2018012652A (ja) | 杜仲葉抽出物の脱色方法、脱色された杜仲葉抽出物及びこれらの利用 | |
CN113573722A (zh) | 包含姜黄素和辅酶q10的组合物 | |
KR101163380B1 (ko) | 혈중 콜레스테롤과 중성지방 저하용 나노키토산 조성물 | |
CN107864621A (zh) | 包含天然材料之颗粒和提取物的纳米混悬液 | |
DE68909057T2 (de) | Durch hitze dehydratisierte emulsionen. | |
CN107184566A (zh) | 含有叶黄素的药物组合物及其制备方法和制剂 | |
CA2304493A1 (en) | Flavonolignan preparations, especially silymarin preparations | |
JP2014150782A (ja) | ローヤルゼリー含有錠剤及びその製造方法 | |
KR102093821B1 (ko) | 페오닥틸럼 추출물을 제조하는 방법 | |
CN106074495A (zh) | 降低黄曲霉毒素生物利用度的儿茶素纳米粒的制备方法 | |
WO2022045371A1 (ja) | 組成物およびその組成物の製造方法、脂溶性成分の吸収性を向上させる方法、脂溶性成分の抽出効率を向上させる方法、脂溶性成分 | |
US20060029690A1 (en) | Buckwheat compound and method of obtaining the same for treatment of hyperglycemia | |
CN110167534A (zh) | 粉末固体组合物、它们的制备方法、其制剂和用途 | |
Jain et al. | Formulation and Evaluation of Phytosomes Loaded with Pithecellobium Bijeninum Leaf Extract | |
CN109846865A (zh) | 一种姜黄素制剂及其制备方法 | |
Ardestani et al. | Melissa officinalis extraction with nanoencapsulation By chitosan as an ecofriendly compound | |
CN116869934B (zh) | 一种多酚类物质的超分子纳米胶体及其制备方法 | |
CN108079314B (zh) | 辅酶q10与二十八烷醇环糊精多元超分子包合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |